The proxy fight outcome is binary and will be resolved at the June 9 meeting. With all three major proxy advisors backing management, the incumbent slate is heavily favored. A DOMA win would introduce significant uncertainty around capital allocation and strategic direction. Monitor vote results post-meeting for potential board composition changes.
PCRX drugs
PCRX drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 5 $22.75entry
- T+1 · 5mo ago +0.48%α +0.26% · $22.86
- T+5 · 5mo ago +1.05%α +0.49% · $22.99
- T+20 · 4mo ago +12.48%α +10.62% · $25.59
- T+60 · 3mo ago +13.85%α +9.85% · $25.90
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Pacira BioSciences issued a DEFA14A press release reminding stockholders to vote FOR management's three director nominees (Christopher Christie, Samit Hirawat, MD, Thomas Wiggans) on the BLUE proxy card at the June 9, 2026 annual meeting, and AGAINST all three nominees from activist investor DOMA Perpetual Capital Management. The filing highlights record 2025 financial results, Q1 2026 revenue growth across all commercial products (EXPAREL +5%, ZILRETTA +15%, iovera +21% YoY), and endorsements from all three leading proxy advisory firms (ISS, Glass Lewis, Egan-Jones) supporting management's slate.
Key Financial Metrics
Key Facts
- Annual meeting scheduled for June 9, 2026
- Management nominees: Christopher Christie, Samit Hirawat, MD, Thomas Wiggans
- Activist DOMA Perpetual Capital Management nominated three director candidates
- All three proxy advisory firms (ISS, Glass Lewis, Egan-Jones) recommend FOR management's nominees
- Q1 2026 EXPAREL revenue $143.3M (+5% YoY), ZILRETTA $26.8M (+15%), iovera $6.2M (+21%)
- 2025 record total revenue $726.4M, GAAP gross margin 79.4%, non-GAAP gross margin 81.2%
- Goldman Sachs acting as financial advisor, Perkins Coie as legal counsel
- Key pipeline catalysts expected in 2026: Phase 2 PCRX-201 data in knee OA, registrational studies for ZILRETTA (shoulder OA) and iovera (spasticity)
Financial Impact
Record 2025 revenue of $726.4M with 79.4% GAAP gross margin; Q1 2026 product revenue growth of 5-21% YoY across portfolio
Risk Factors
- Activist DOMA could win board seats despite proxy advisor opposition, potentially disrupting strategy
- Pipeline readouts (PCRX-201 Phase 2, registrational studies) carry binary clinical risk
- Revenue growth is modest (5-21% across products) and may not satisfy activist demands for faster value creation
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001628280-26-040814 |
| Document: 0001628280-26-040814-index-headers.html | 0001628280-26-040814 |
| Document: 0001628280-26-040814-index.html | 0001628280-26-040814 |
| Document: 0001628280-26-040814.txt | 0001628280-26-040814 |
Track record
29 reports on PCRX
5 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +42.26% at T+60 after the Aug 6, 2026 report. 8 of 9 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Bearish 6/10 Entry $36.46 Now $36.48 −0.05% settles Dec 14
- Nov 12, 20264d ago SC TO-T/A Mixed 7/10 Entry $36.46 Now $36.48 +0.05% settles Dec 14
- Nov 12, 20264d ago SC 14D-9/A Neutral 3/10 Entry $36.46 Now $36.48 +0.05% settles Dec 14
- Nov 5, 202611d ago 8-K Neutral 5/10 Entry $36.43 Now $36.48 +0.14% settles Dec 7
- Nov 3, 202613d ago SC 14D-9/A Neutral 3/10 Entry $36.40 Now $36.48 +0.22% settles Dec 3
- Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
- Oct 30, 202617d ago SC 14D-9 Bullish 7/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
- Oct 30, 202617d ago SC TO-T Mixed 7/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
- Oct 13, 20264w ago SC 13D/A Bearish 7/10 Entry $36.40 to $36.46 Now $36.48 −0.22% ▼ −0.16% −1.44% vs SPY
- Oct 8, 20265w ago SC TO-C Bullish 7/10 Entry $36.31 to $36.43 Now $36.48 +0.47% ▲ +0.33% +5.89% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers